METHOD AND KIT FOR DETECTING COMBINED THERAPEUTIC EFFECT OF INTERFERON AND RIBAVIRIN
PROBLEM TO BE SOLVED: To provide a method by which the effectiveness of combined therapy of interferon and ribavirin can be determined before starting the therapy or at an early stage after starting the therapy. SOLUTION: The method for detecting the combined therapeutic effect of the interferon and...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | TSUBOUCHI HIROHITO UTO HIROFUMI ETO NOZOMI OKI MAYUKO TAKAHAMA YUKA |
| description | PROBLEM TO BE SOLVED: To provide a method by which the effectiveness of combined therapy of interferon and ribavirin can be determined before starting the therapy or at an early stage after starting the therapy. SOLUTION: The method for detecting the combined therapeutic effect of the interferon and the ribavirin uses the difference in expression levels of a specific biomaterial discovered by the following comparison as an index exhibiting the effectiveness of the combined therapy of the interferon and the ribavirin by comparing the expression levels of the specific biomaterial in each cell before and after administration of the interferon and the ribavirin to detect the combined therapeutic effects of the interferon and the ribavirin in a testee of a carrier of hepatitis C virus. The specific biomaterial is at least one selected from the group consisting of ANXA3, PCNA, LMNB1, PAK1, 4EBP1, KARS, PSME2, ENO1, STAT1, PHB, SP-100, and PPP1CB. COPYRIGHT: (C)2009,JPO&INPIT |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_JP2009178057A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JP2009178057A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_JP2009178057A3</originalsourceid><addsrcrecordid>eNqNi7EKwjAQQLs4iPoPh7sQFWkd0-RiTumlHKdrKRIn0UL9fxTxA5ze8N6bFtqgxuTBsocTKYQk4FHRKfEBXGpqYvSgEcW2eFZygCF8NKQAxIoSUBJ_f6HaXkiI58Xk1t_HvPhxViwDqourPDy7PA79NT_yqzu2G2P267Iyu9Ju_4reXGcwTQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>METHOD AND KIT FOR DETECTING COMBINED THERAPEUTIC EFFECT OF INTERFERON AND RIBAVIRIN</title><source>esp@cenet</source><creator>TSUBOUCHI HIROHITO ; UTO HIROFUMI ; ETO NOZOMI ; OKI MAYUKO ; TAKAHAMA YUKA</creator><creatorcontrib>TSUBOUCHI HIROHITO ; UTO HIROFUMI ; ETO NOZOMI ; OKI MAYUKO ; TAKAHAMA YUKA</creatorcontrib><description>PROBLEM TO BE SOLVED: To provide a method by which the effectiveness of combined therapy of interferon and ribavirin can be determined before starting the therapy or at an early stage after starting the therapy. SOLUTION: The method for detecting the combined therapeutic effect of the interferon and the ribavirin uses the difference in expression levels of a specific biomaterial discovered by the following comparison as an index exhibiting the effectiveness of the combined therapy of the interferon and the ribavirin by comparing the expression levels of the specific biomaterial in each cell before and after administration of the interferon and the ribavirin to detect the combined therapeutic effects of the interferon and the ribavirin in a testee of a carrier of hepatitis C virus. The specific biomaterial is at least one selected from the group consisting of ANXA3, PCNA, LMNB1, PAK1, 4EBP1, KARS, PSME2, ENO1, STAT1, PHB, SP-100, and PPP1CB. COPYRIGHT: (C)2009,JPO&INPIT</description><language>eng</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS OR TEST PAPERS THEREFOR ; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ; ENZYMOLOGY ; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS ; METALLURGY ; MICROBIOLOGY ; MUTATION OR GENETIC ENGINEERING ; PROCESSES OF PREPARING SUCH COMPOSITIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2009</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20090813&DB=EPODOC&CC=JP&NR=2009178057A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,778,883,25547,76298</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20090813&DB=EPODOC&CC=JP&NR=2009178057A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>TSUBOUCHI HIROHITO</creatorcontrib><creatorcontrib>UTO HIROFUMI</creatorcontrib><creatorcontrib>ETO NOZOMI</creatorcontrib><creatorcontrib>OKI MAYUKO</creatorcontrib><creatorcontrib>TAKAHAMA YUKA</creatorcontrib><title>METHOD AND KIT FOR DETECTING COMBINED THERAPEUTIC EFFECT OF INTERFERON AND RIBAVIRIN</title><description>PROBLEM TO BE SOLVED: To provide a method by which the effectiveness of combined therapy of interferon and ribavirin can be determined before starting the therapy or at an early stage after starting the therapy. SOLUTION: The method for detecting the combined therapeutic effect of the interferon and the ribavirin uses the difference in expression levels of a specific biomaterial discovered by the following comparison as an index exhibiting the effectiveness of the combined therapy of the interferon and the ribavirin by comparing the expression levels of the specific biomaterial in each cell before and after administration of the interferon and the ribavirin to detect the combined therapeutic effects of the interferon and the ribavirin in a testee of a carrier of hepatitis C virus. The specific biomaterial is at least one selected from the group consisting of ANXA3, PCNA, LMNB1, PAK1, 4EBP1, KARS, PSME2, ENO1, STAT1, PHB, SP-100, and PPP1CB. COPYRIGHT: (C)2009,JPO&INPIT</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS OR TEST PAPERS THEREFOR</subject><subject>CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES</subject><subject>ENZYMOLOGY</subject><subject>MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>PROCESSES OF PREPARING SUCH COMPOSITIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2009</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNi7EKwjAQQLs4iPoPh7sQFWkd0-RiTumlHKdrKRIn0UL9fxTxA5ze8N6bFtqgxuTBsocTKYQk4FHRKfEBXGpqYvSgEcW2eFZygCF8NKQAxIoSUBJ_f6HaXkiI58Xk1t_HvPhxViwDqourPDy7PA79NT_yqzu2G2P267Iyu9Ju_4reXGcwTQ</recordid><startdate>20090813</startdate><enddate>20090813</enddate><creator>TSUBOUCHI HIROHITO</creator><creator>UTO HIROFUMI</creator><creator>ETO NOZOMI</creator><creator>OKI MAYUKO</creator><creator>TAKAHAMA YUKA</creator><scope>EVB</scope></search><sort><creationdate>20090813</creationdate><title>METHOD AND KIT FOR DETECTING COMBINED THERAPEUTIC EFFECT OF INTERFERON AND RIBAVIRIN</title><author>TSUBOUCHI HIROHITO ; UTO HIROFUMI ; ETO NOZOMI ; OKI MAYUKO ; TAKAHAMA YUKA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_JP2009178057A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2009</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS OR TEST PAPERS THEREFOR</topic><topic>CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES</topic><topic>ENZYMOLOGY</topic><topic>MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>PROCESSES OF PREPARING SUCH COMPOSITIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>TSUBOUCHI HIROHITO</creatorcontrib><creatorcontrib>UTO HIROFUMI</creatorcontrib><creatorcontrib>ETO NOZOMI</creatorcontrib><creatorcontrib>OKI MAYUKO</creatorcontrib><creatorcontrib>TAKAHAMA YUKA</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>TSUBOUCHI HIROHITO</au><au>UTO HIROFUMI</au><au>ETO NOZOMI</au><au>OKI MAYUKO</au><au>TAKAHAMA YUKA</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>METHOD AND KIT FOR DETECTING COMBINED THERAPEUTIC EFFECT OF INTERFERON AND RIBAVIRIN</title><date>2009-08-13</date><risdate>2009</risdate><abstract>PROBLEM TO BE SOLVED: To provide a method by which the effectiveness of combined therapy of interferon and ribavirin can be determined before starting the therapy or at an early stage after starting the therapy. SOLUTION: The method for detecting the combined therapeutic effect of the interferon and the ribavirin uses the difference in expression levels of a specific biomaterial discovered by the following comparison as an index exhibiting the effectiveness of the combined therapy of the interferon and the ribavirin by comparing the expression levels of the specific biomaterial in each cell before and after administration of the interferon and the ribavirin to detect the combined therapeutic effects of the interferon and the ribavirin in a testee of a carrier of hepatitis C virus. The specific biomaterial is at least one selected from the group consisting of ANXA3, PCNA, LMNB1, PAK1, 4EBP1, KARS, PSME2, ENO1, STAT1, PHB, SP-100, and PPP1CB. COPYRIGHT: (C)2009,JPO&INPIT</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_JP2009178057A |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ENZYMOLOGY MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING PROCESSES OF PREPARING SUCH COMPOSITIONS SPIRITS VINEGAR WINE |
| title | METHOD AND KIT FOR DETECTING COMBINED THERAPEUTIC EFFECT OF INTERFERON AND RIBAVIRIN |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T17%3A03%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=TSUBOUCHI%20HIROHITO&rft.date=2009-08-13&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EJP2009178057A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |